A phase I study of two administration schedules of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumors
Munzert, G., Steinbild, S., Frost, A., Hedborn, S., Rentschler, J., Kaiser, R., Trommeshauser, D., Hoffmann, M., Steegmaier, M., Mross, K.
Published in Journal of clinical oncology (20.06.2006)
Published in Journal of clinical oncology (20.06.2006)
Get full text
Journal Article